Upstream Bio, Inc. (NASDAQ: UPB) is a publicly traded clinical-stage biotechnology company. As such, it is not owned by a single private entity, but rather collectively held by institutional mutual funds, venture capital firms, healthcare specialized asset managers, and public retail shareholders trading on the Nasdaq exchange.